Aplastic Anemia Treatment Options: Immunosuppressive Therapy (ATG and Cyclosporine) or Bone Marrow Transplant — A Decision Framework for International Patients, Families, and Physicians Considering Care in China

What Is Aplastic Anemia, and Why Does Treatment Choice Matter So Much?

Acquired aplastic anemia occurs when the immune system attacks the bone marrow's blood-forming stem cells, leaving the marrow unable to produce enough red cells, white cells, and platelets. Doctors generally classify severity — non-severe, severe, or very severe — based on blood counts and bone marrow findings, and this classification, together with age and donor availability, largely determines which treatment path is recommended. Because severe forms carry meaningful risk from infection and bleeding, the decision between immunosuppressive therapy and transplant is usually made promptly after diagnosis, not deferred.

Unlike many blood cancers, aplastic anemia is not malignant — but it is managed by the same hematology and transplant teams, and shares many of the same donor-matching and transplant-protocol considerations as leukemia and other blood disorders.

The Two Main Treatment Paths, Compared

Neither path is inherently superior. Published outcomes for both approaches have improved substantially over the past two decades, and the right choice depends on the specific factors discussed below — not a fixed rule that applies to every patient.

Why "No Donor Available" Increasingly Does Not Mean What It Used To

For decades, "no matched donor" effectively meant no matched sibling donor — and for most patients in that situation, the default recommendation was immunosuppressive therapy, with transplant reserved for those who failed to respond or later relapsed. This made sense when alternative donor transplant carried substantially higher risk than it does today.

That calculation is shifting. Every parent is a haploidentical (half-matched) donor for their child, and adult children and roughly half of siblings are haploidentical matches as well — meaning a family donor is available for the great majority of patients, regardless of whether a fully matched sibling exists. As haploidentical transplant protocols — including the Beijing Protocol developed in China — have matured, published outcomes for aplastic anemia using haploidentical donors have become broadly comparable to matched donor transplant at experienced centres.

This does not mean transplant is now automatically preferred over immunosuppressive therapy whenever a family donor exists. It means the historical assumption — that "no matched sibling" should default to a prolonged trial of immunosuppressive therapy — is being reconsidered case by case, particularly for younger patients at centres with substantial haploidentical transplant experience.

What China's Registry Data Shows About Aplastic Anemia Transplant Practice

Nationwide CCBMTR registry data covering 22,381 pediatric hematopoietic cell transplants in China between 2017 and 2024 provides one of the clearest illustrations of how this shift plays out in practice.

The registry reports failure-free survival (FFS) of 82–92% for aplastic anemia transplant in children, described as broadly comparable across donor types, including haploidentical donors. These are registry-level figures — individual outcomes depend on disease severity, prior immunosuppressive therapy, donor selection, conditioning regimen, and other clinical variables, and require review of a specific patient's records by a specialist team.

For families and physicians, this data reflects a transplant program built around routine use of parent and sibling donors — not a program where the absence of a matched sibling automatically triggers months of immunosuppressive therapy before transplant is considered. More detail on the underlying registry findings is available in our summary of 22,381 pediatric transplants in the CCBMTR registry. This article is also part of ChinaMed Waypoint's pediatric leukemia and blood disorders resources for international families, given how closely aplastic anemia care overlaps with pediatric transplant decision-making.

When Immunosuppressive Therapy Remains the Appropriate First Step

None of this means transplant is preferable for every patient. Immunosuppressive therapy remains the appropriate first-line approach in several common situations:

What Happens If Immunosuppressive Therapy Does Not Work?

Response to IST is typically assessed over three to six months. A meaningful proportion of patients do not achieve an adequate response, and among those who do, a further proportion relapse over subsequent years. When either occurs, transplant evaluation — using whichever donor type is available — is usually initiated promptly, given the ongoing risks of severe cytopenia and the possibility of clonal evolution the longer the disease remains unresolved.

For families in this situation, our guide on donor options when no matched unrelated donor is available explains the alternatives — haploidentical family donor, cord blood, and mismatched unrelated donor — in more detail.

Supportive Care During Aplastic Anemia Treatment

Whether a patient is undergoing immunosuppressive therapy or preparing for transplant, the period of low blood counts requires careful supportive management — infection prevention, transfusion support, and close monitoring form the backbone of care throughout treatment.

At Chinese hematology centres, supportive care alongside standard treatment may also include integrative approaches such as acupuncture and Traditional Chinese Medicine for fatigue, sleep, and appetite support during intensive treatment. These are positioned as complementary to — never as a replacement for — immunosuppressive therapy, transplant conditioning, or any other primary disease-directed treatment.

See the supportive care and Traditional Chinese Medicine resources for more on what integrative supportive care during hematology treatment in China may involve.